X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs VENUS REMEDIES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA VENUS REMEDIES AUROBINDO PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 18.9 -4.1 - View Chart
P/BV x 4.7 0.2 3,101.1% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 AUROBINDO PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
VENUS REMEDIES
Mar-18
AUROBINDO PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs895126 710.9%   
Low Rs62261 1,018.0%   
Sales per share (Unadj.) Rs254.6301.8 84.4%  
Earnings per share (Unadj.) Rs39.3-24.9 -157.9%  
Cash flow per share (Unadj.) Rs46.62.5 1,830.4%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.0293.3 54.5%  
Shares outstanding (eoy) m585.8812.34 4,747.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.00.3 961.6%   
Avg P/E ratio x19.3-3.8 -513.7%  
P/CF ratio (eoy) x16.336.7 44.3%  
Price / Book Value ratio x4.70.3 1,487.3%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,3901,154 38,515.7%   
No. of employees `00014.00.9 1,511.6%   
Total wages/salary Rs m17,678393 4,497.0%   
Avg. sales/employee Rs Th10,667.84,026.1 265.0%   
Avg. wages/employee Rs Th1,264.3425.0 297.5%   
Avg. net profit/employee Rs Th1,645.8-331.8 -496.1%   
INCOME DATA
Net Sales Rs m149,1573,724 4,005.2%  
Other income Rs m1,15923 5,150.7%   
Total revenues Rs m150,3163,747 4,012.1%   
Gross profit Rs m34,343395 8,698.8%  
Depreciation Rs m4,276338 1,264.1%   
Interest Rs m667354 188.3%   
Profit before tax Rs m30,558-275 -11,100.0%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,59732 24,039.6%   
Profit after tax Rs m23,012-307 -7,498.2%  
Gross profit margin %23.010.6 217.2%  
Effective tax rate %24.9-11.5 -216.6%   
Net profit margin %15.4-8.2 -187.2%  
BALANCE SHEET DATA
Current assets Rs m92,0622,638 3,490.3%   
Current liabilities Rs m66,2232,305 2,873.5%   
Net working cap to sales %17.38.9 193.7%  
Current ratio x1.41.1 121.5%  
Inventory Days Days106135 78.3%  
Debtors Days Days6846 146.1%  
Net fixed assets Rs m62,9194,871 1,291.8%   
Share capital Rs m586123 474.8%   
"Free" reserves Rs m93,1333,496 2,664.2%   
Net worth Rs m93,7193,619 2,589.6%   
Long term debt Rs m1,8141,374 132.0%   
Total assets Rs m162,4947,509 2,164.1%  
Interest coverage x46.80.2 20,989.2%   
Debt to equity ratio x00.4 5.1%  
Sales to assets ratio x0.90.5 185.1%   
Return on assets %14.60.6 2,308.4%  
Return on equity %24.6-8.5 -289.6%  
Return on capital %32.71.6 2,069.3%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m75,8380-   
Fx outflow Rs m30,224517 5,851.8%   
Net fx Rs m45,613-517 -8,831.2%   
CASH FLOW
From Operations Rs m32,786514 6,373.6%  
From Investments Rs m-17,870-123 14,517.0%  
From Financial Activity Rs m-19,153-387 4,947.7%  
Net Cashflow Rs m-4,2394 -100,921.4%  

Share Holding

Indian Promoters % 54.1 32.9 164.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 4,416.7%  
FIIs % 27.7 0.6 4,775.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 66.4 15.4%  
Shareholders   69,601 20,121 345.9%  
Pledged promoter(s) holding % 8.6 36.4 23.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUVEN LIFE  MERCK LTD  NOVARTIS  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Related Views on News

SUVEN LIFE Surges by 6%; BSE HEALTHCARE Index Up 2.0% (Market Updates)

Sep 25, 2018 | Updated on Sep 25, 2018

SUVEN LIFE share price has surged by 6% and its current market price is Rs 283. The BSE HEALTHCARE is up by 2.0%. The top gainers in the BSE HEALTHCARE Index are SUVEN LIFE (up 5.9%) and AUROBINDO PHARMA (up 5.4%). The top losers are FORTIS HEALTHCARE and IPCA LABS (down 0.1%).

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 25, 2018 03:37 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - VENUS REMEDIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS